Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs

Bone

Volumn 71, Issue , 2015, Pages 58-62

  Burr, David B ^a   Liu, Ziyue ^a   Allen, Matthew R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical femoral fractures; Bisphosphonates; Cortical bone; Toughness

Indexed keywords

ALENDRONIC ACID;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEAGLE; BONE DENSITY; BONE STRENGTH; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; DRUG EXPOSURE; ENERGY ABSORPTION; FEMALE; NONHUMAN; RIB; TREATMENT DURATION; ANIMAL; ANIMAL MODEL; BIOMECHANICS; BONE; CHEMICALLY INDUCED; DOG; DRUG ADMINISTRATION; DRUG EFFECTS; FRACTURE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; STATISTICAL MODEL; TIME;

ADMINISTRATION, ORAL; ALENDRONATE; ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; LINEAR MODELS; MODELS, ANIMAL; TIME FACTORS;

EID: 84908637567     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.10.010     Document Type: Article

References (22)

1. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65.
2. Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014, 29:1-23.
3. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010, 362:1825-1827.
4. Mashiba T., Hirano T., Turner C.H., Forwood M., Johnston C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
5. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003, 18:512-520.
6. Allen M., Iwata K., Phipps R., Burr D. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
7. Allen M.R., Iwata K., Sato M., Burr D.B. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 2006, 39:1130-1135.
8. Allen M., Burr D. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007, 22:1759-1765.
9. Yamagami Y., Mashiba T., Iwata K., Tanaka M., Nozaki K., Yamamoto T. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. Bone 2013, 54:1-7.
10. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3years of daily treatment. Calcif Tissue Int 2008, 82:354-360.
11. Tang S.Y., Allen M.R., Phipps R., Burr D.B., Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009, 20:887-894.
12. Luo T.D., Allen M.R. Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness. Bone 2013, 56:199-203.
13. Mashiba T., Turner C.H., Hirano T., Forwood M., Johnston C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
14. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004, 19:999-1005.
15. Burr D., Diab T., Koivunemi A., Koivunemi M., Allen M. Effects of 1 to 3years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res 2009, 27:1288-1292.
16. Bajaj D., Geissler J.R., Allen M.R., Burr D.B., Fritton J.C. The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone 2014, 64:57-64.
17. Allen M., Kubek D., Burr D. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2010, 25:98-105.
18. Dell R.M., Adams A.L., Greene D.F., Funahashi T.T., Silverman S.L., Eisemon E.O., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012, 27:2544-2550.
19. Brown J.P., Morin S., Leslie W., Papaioannou A., Cheung A.M., Davison K.S., et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 2014, 60:324-333.
20. Balena R., Toolan B., Shea M., Markatos A., Myers E., Lee S., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92:2577.
21. Martin R.B., Butcher R.L., Sherwood L.L., Buckendahl P. Effects of ovariectomy in beagle dogs. Bone 1987, 8:23-31.
22. Nagal S., Shindo H. Mechanical strength of bone in canine osteoporosis model: Relationship between bone mineral content and bone fragility. J Orthop Sci 1997, 2:428-433.